Previous close | 1.6000 |
Open | 1.6000 |
Bid | 1.2000 |
Ask | 1.3000 |
Strike | 1.50 |
Expiry date | 2024-09-20 |
Day's range | 1.6000 - 1.6000 |
Contract range | N/A |
Volume | |
Open interest | 27 |
Ionis (IONS) and Biogen (BIIB) stop developing their experimental ALS drug after a phase I/II study failed to show improvement in patients.
Per the FDA, the data submitted by Ascendis (ASND) for its hormone replacement therapy constitutes a major amendment to its previously-submitted data. A final decision is expected by Aug 14.
A week ago, Heron Therapeutics, Inc. ( NASDAQ:HRTX ) came out with a strong set of quarterly numbers that could...